101 related articles for article (PubMed ID: 25298182)
1. Vaccine and oncogenic strains of gallid herpesvirus 2 contain specific subtype variations in the 5' region of the latency-associated transcript that evolve in vitro and in vivo.
Labaille J; Lion A; Boissel E; Trapp S; Nair V; Rasschaert D; Dambrine G
Arch Virol; 2015 Jan; 160(1):161-71. PubMed ID: 25298182
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Gallid herpesvirus 2 with interrupted meq genes confers safe and efficacious protection against virulent field strains.
Zhang Y; Liu C; Yan F; Liu A; Cheng Y; Li Z; Sun G; Lv H; Wang X
Vaccine; 2017 Aug; 35(36):4695-4701. PubMed ID: 28754487
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of immunoprotection between vaccination with meq-deleted Marek's disease virus and vaccine strain CVI988/Rispens].
Duan L; Su S; Wang Y; Li S; Sun P; Chen W; Cui Z
Wei Sheng Wu Xue Bao; 2014 Nov; 54(11):1353-61. PubMed ID: 25752142
[TBL] [Abstract][Full Text] [Related]
4. Increased virulence of Marek's disease virus type 1 vaccine strain CV1988 after adaptation to qt35 cells.
Majerciak V; Valkova A; Szabová D; Geerligs H; Zelník V
Acta Virol; 2001 Apr; 45(2):101-8. PubMed ID: 11719980
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a very virulent Marek's disease virus mutant expressing the pp38 protein from the serotype 1 vaccine strain CVI988/Rispens.
Lee LF; Cui X; Cui Z; Gimeno I; Lupiani B; Reddy SM
Virus Genes; 2005 Aug; 31(1):73-80. PubMed ID: 15965611
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus.
Witter RL; Lee LF; Fadly AM
Avian Dis; 1995; 39(2):269-84. PubMed ID: 7677647
[TBL] [Abstract][Full Text] [Related]
7. Host genetic resistance to Marek's disease sustains protective efficacy of herpesvirus of turkey in both experimental and commercial lines of chickens.
Chang S; Xie Q; Dunn JR; Ernst CW; Song J; Zhang H
Vaccine; 2014 Apr; 32(16):1820-7. PubMed ID: 24530405
[TBL] [Abstract][Full Text] [Related]
8. Viral kinetics, shedding profile, and transmission of serotype 1 Marek's disease vaccine Rispens/CVI988 in maternal antibody-free chickens.
Islam T; Renz KG; Walkden-Brown SW; Ralapanawe S
Avian Dis; 2013 Jun; 57(2 Suppl):454-63. PubMed ID: 23901761
[TBL] [Abstract][Full Text] [Related]
9. Detection and differentiation of CVI988 (Rispens vaccine) from other serotype 1 Marek's disease viruses.
Gimeno IM; Dunn JR; Cortes AL; El-Gohary Ael-G; Silva RF
Avian Dis; 2014 Jun; 58(2):232-43. PubMed ID: 25055627
[TBL] [Abstract][Full Text] [Related]
10. In vitro characterization of the Meq proteins of Marek's disease virus vaccine strain CVI988.
Ajithdoss DK; Reddy SM; Suchodolski PF; Lee LF; Kung HJ; Lupiani B
Virus Res; 2009 Jun; 142(1-2):57-67. PubMed ID: 19189855
[TBL] [Abstract][Full Text] [Related]
11. Vaccination against Marek's disease reduces telomerase activity and viral gene transcription in peripheral blood leukocytes from challenged chickens.
Debba-Pavard M; Ait-Lounis A; Soubieux D; Rasschaert D; Dambrine G
Vaccine; 2008 Sep; 26(38):4904-12. PubMed ID: 18680776
[TBL] [Abstract][Full Text] [Related]
12. Common occurrence of Gallid herpesvirus-2 with reticuloendotheliosis virus in chickens caused by possible contamination of vaccine stocks.
Woźniakowski G; Mamczur A; Samorek-Salamonowicz E
J Appl Microbiol; 2015 Apr; 118(4):803-8. PubMed ID: 25641090
[TBL] [Abstract][Full Text] [Related]
13. [Marek's disease virus can infect chicken brain microglia and promote the transcription of toll-like receptor 15 and 1LB genes].
Yang QL; Chen H; Wei P
Bing Du Xue Bao; 2011 Jan; 27(1):18-25. PubMed ID: 21462502
[TBL] [Abstract][Full Text] [Related]
14. Variations in the H/ACA box sequence of viral telomerase RNA of isolates of CVI988 Rispens vaccine.
Debba-Pavard M; Le Galludec H; Dambrine G; Rasschaert D
Arch Virol; 2008; 153(8):1563-8. PubMed ID: 18594940
[TBL] [Abstract][Full Text] [Related]
15. Differentiation between pathogenic serotype 1 isolates of Marek's disease virus and the Rispens CVI988 vaccine in Australia using real-time PCR and high resolution melt curve analysis.
Renz KG; Cheetham BF; Walkden-Brown SW
J Virol Methods; 2013 Jan; 187(1):144-52. PubMed ID: 23041147
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a Gallid herpesvirus 2 strain with novel reticuloendotheliosis virus long terminal repeat inserts.
Zhang YP; Bao KY; Sun GR; Lv HC; Cui HY; Gao YL; Wang XM; Liu CJ
Virus Genes; 2017 Jun; 53(3):386-391. PubMed ID: 28194622
[TBL] [Abstract][Full Text] [Related]
17. Detection of specific UL49 sequences of Marek's disease virus CVI988/Rispens strain using loop-mediated isothermal amplification.
Woźniakowski G; Niczyporuk JS
J Virol Methods; 2015 Sep; 221():22-8. PubMed ID: 25920566
[TBL] [Abstract][Full Text] [Related]
18. Comparative genomic sequence analysis of the Marek's disease vaccine strain SB-1.
Spatz SJ; Schat KA
Virus Genes; 2011 Jun; 42(3):331-8. PubMed ID: 21336949
[TBL] [Abstract][Full Text] [Related]
19. Cytokine responses and inducible nitrous oxide synthase expression patterns in neonatal chicken brain microglia infected with very virulent Marek's disease virus strain YL040920.
Yang Q; Wei P; Chen H
Vet Immunol Immunopathol; 2011 Jul; 142(1-2):14-24. PubMed ID: 21501879
[TBL] [Abstract][Full Text] [Related]
20. Characterization of four very virulent Argentinian strains of Marek's disease virus and the influence of one of those isolates on synergism between Marek's disease vaccine viruses.
Buscaglia C; Nervi P; Risso M
Avian Pathol; 2004 Apr; 33(2):190-5. PubMed ID: 15276986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
